医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CORE Diagnostics Appoints New CEO to Accelerate Growth

2014年06月24日 PM11:30
このエントリーをはてなブックマークに追加


 

PALO ALTO, Calif.

CORE Diagnostics, Inc., the leading high-end clinical diagnostics laboratory, announced today the appointment of K. Balachandran (Bala) as chief executive officer, effective immediately.

With more than 25 years of experience with large publicly traded companies both domestically and internationally, Bala brings to CORE hands-on knowledge of the healthcare industry and the high-tech sector. Most recently, Bala served as the chief operating officer of NeuroMetrix, Inc., where he successfully transitioned the company’s strategic direction to point-of-care diabetic neuropathy and put the company on a growth trajectory. Previously, after 8 years with HP in various program management and P&L roles based in California, including director of the company’s strategic alliances, he joined Cardinal Health as vice president and general manager of the NeuroCare business division and oversaw a global P&L of $150 million. Prior to that, Bala was a leader at Nicolet Biomedical in Madison, Wis., as the director for the Asia Pacific business and advanced to become vice president of Nicolet’s international business.

“Bala’s intimate knowledge of the healthcare industry, customer focus and P&L experience coupled with his track record in developing international markets are an excellent fit with our needs,” said Dr. Ajit Singh, managing director and general partner at Artiman Ventures, and chairman of the board of CORE Diagnostics. “We are very pleased to have him on board and look forward to his contributions as we continue developing CORE Diagnostics into a premier clinical pathology laboratory and contract research organization.”

CORE Diagnostics is focused on bringing the most advanced testing techniques and expertise to routine clinical practice. The company offers a rich menu of high-end tests and provides patients with peace of mind by delivering second opinions on every test from at least two specialists from its global panel of pathologists.

“It is a great privilege to lead the extremely talented people at CORE Diagnostics at such a time when the company is positioned for growth, both in its clinical pathology biopharma research initiatives globally,” said K. Balachandran, CEO at CORE Diagnostics.

ABOUT CORE DIAGNOSTICS

CORE Diagnostics is a clinical laboratory offering next generation diagnostics for disease stratification and therapy selection. With offices in Palo Alto, CA, and Gurgaon, India, CORE Diagnostics offers a comprehensive menu of specialized, advanced diagnostic testing in the areas of cardiology, oncology, reproductive disorders, endocrinology and infectious diseases. The company also deploys next generation sequencing in clinical applications and uses digital pathology for enabling concurrent global review of test results. CORE Diagnostics is backed by Artiman Ventures, the leading white space investment firm based in Palo Alto, Calif. For more information, please visit www.corediagnostics.in.

CONTACT

For CORE Diagnostics
Keely Hopkins, 415-365-0361

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402